<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02824614</url>
  </required_header>
  <id_info>
    <org_study_id>Poly Gut</org_study_id>
    <nct_id>NCT02824614</nct_id>
  </id_info>
  <brief_title>Effect of the Natural Sweeteners Erythritol and Xylitol on Gut Microbiota and Glucose Metabolism in Obese Volunteers</brief_title>
  <official_title>Effect of the Natural Sweeteners Erythritol and Xylitol on Gut Microbiota and Glucose Metabolism in Obese Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sugar alcohols such as xylitol and erythritol are increasingly popular as sugar substitutes
      in the food industry and are also recommended to diabetic patients. Both substances are
      already in use in the food industry and are freely available. Since the 1970s, beneficial
      effects on oral health could be demonstrated as oral bacteria were influenced positively.
      Animal studies showed an increase in gut Clostridium perfringens after xylitol intake;
      certainly a non-desirable effect. However, studies on effects of erythritol and xylitol on
      the human gut microbiota are lacking so far. In this trial, investigators aim to examine
      whether gut microbiota and glucose tolerance can be influenced by polyol intake in a
      non-diabetic but obese cohort.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose tolerance measured with oral glucose tolerance test</measure>
    <time_frame>change from baseline to 8 weeks after polyol intake</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Human gut microbiota composition measured with metagenomic shotgun sequencing</measure>
    <time_frame>change from baseline to 8 weeks after polyol intake</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut microbial-related metabolites in feces</measure>
    <time_frame>change from baseline to 8 weeks after polyol intake</time_frame>
    <description>Metabolomic analysis of the bacterial metabolites present in the feces by combining nuclear magnetic resonance (1H-NMR) and mass spectrometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal tolerance assessed by questionnaire</measure>
    <time_frame>change from baseline to 8 weeks after polyol intake</time_frame>
    <description>Gastrointestinal Symptoms Rating Scale (Svedlund et al)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut microbial-related metabolites in urine</measure>
    <time_frame>change from baseline to 8 weeks after polyol intake</time_frame>
    <description>Metabolomic analysis of the bacterial metabolites present in the urine by combining nuclear magnetic resonance (1H-NMR) and mass spectrometry</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>20 obese, non-diabetic candidates will serve as control-group. All assessments are carried out just as in the intervention groups.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E967-Xylitol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 obese, non-diabetic candidates will receive a daily dose of 24g of xylitol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E968-Erythritol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 obese, non-diabetic candidates will receive a daily dose of 36g of erythritol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>E967-Xylitol</intervention_name>
    <arm_group_label>E967-Xylitol</arm_group_label>
    <other_name>Xylitol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>E968-Erythritol</intervention_name>
    <arm_group_label>E968-Erythritol</arm_group_label>
    <other_name>Erythritol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Obese volunteers (BMI &gt; 30kg/m2)

          -  Aged 18- max. 55 years

          -  Otherwise healthy.

        Exclusion Criteria:

          -  Known cardiovascular disease

          -  Diabetes mellitus

          -  Arterial Hypertension with medication

          -  Dyslipidaemia with medication

          -  Known chronic hepatic disease (NASH, hepatitis).

          -  Known renal disease: kidney failure

          -  Pregnancy

          -  Intake of proton pump inhibitors (PPIs) on a regular basis

          -  Intake of antibiotics within the last 3 months before inclusion

          -  Intake of pro or prebiotics

          -  Chronical diseases of the gastrointestinal tract, history of gastrointestinal surgery
             with major changes to the gastrointestinal tract

          -  Substance abuse, alcohol abuse.

          -  Inability to follow procedures due to psychological disorders, dementia or
             insufficient knowledge of project language (German).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Beglinger, MD</last_name>
    <role>Study Chair</role>
    <affiliation>St. Claraspital klinische Forschungsabteilung</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bettina WÃ¶lnerhanssen, MD</last_name>
    <email>bettina.woelnerhanssen@usb.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>St Claraspital</name>
      <address>
        <city>Basel</city>
        <zip>CH-4016</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bettina K Woelnerhanssen, MD</last_name>
      <email>bettina.woelnerhanssen@usb.ch</email>
    </contact>
    <investigator>
      <last_name>Bettina Woelnerhanssen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2016</study_first_submitted>
  <study_first_submitted_qc>July 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2016</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erythritol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

